Samsung Biologics Co.,Ltd. (KRX:207940)
1,088,000
+24,000 (2.26%)
At close: Jul 24, 2025, 3:30 PM KST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Contract Development and Manufacturing Organization (CDMO) | 3,009.62B | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Organization (CDMO) Growth | 12.54% | Log In | Log In | Log In | Log In | Upgrade |
Other | 382.25B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 31.09% | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Development and Commercialization | 1,537.70B | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Development and Commercialization Growth | 50.71% | Log In | Log In | Log In | Log In | Upgrade |
Product | 4,165.07B | Log In | Log In | Log In | Log In | Upgrade |
Product Growth | 22.39% | Log In | Log In | Log In | Log In | Upgrade |
Other | 382.25B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 31.09% | Log In | Log In | Log In | Log In | Upgrade |
Other | 382.25B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 31.09% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Other | 7.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Organization (CDMO) Operating Profit | 1,119.36B | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Organization (CDMO) Operating Profit Growth | 2.86% | Log In | Log In | Log In | Log In | Upgrade |
Other | 7.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Development and Commercialization Operating Profit | 200.69B | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Development and Commercialization Operating Profit Growth | 688.23% | Log In | Log In | Log In | Log In | Upgrade |
Other | 7.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Domestic | 135.18B | Log In | Log In | Log In | Log In | Upgrade |
Domestic Growth | 17.99% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 2,963.25B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | 25.89% | Log In | Log In | Log In | Log In | Upgrade |
USA | 1,174.14B | Log In | Log In | Log In | Log In | Upgrade |
USA Growth | 20.91% | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic | 274.75B | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic Growth | 7.69% | Log In | Log In | Log In | Log In | Upgrade |